An Open-Label, Non-Randomized, Dose Evaluation, Safety and Pharmacokinetics Phase I Study of AVE8062 in Combination With Cisplatin Administered on Day 1 Followed by Docexatel on Day 2, Every 3 Weeks, in Patients With Advanced Solid Tumors.

Trial Profile

An Open-Label, Non-Randomized, Dose Evaluation, Safety and Pharmacokinetics Phase I Study of AVE8062 in Combination With Cisplatin Administered on Day 1 Followed by Docexatel on Day 2, Every 3 Weeks, in Patients With Advanced Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2014

At a glance

  • Drugs Ombrabulin (Primary) ; Carboplatin; Cisplatin; Docetaxel; Paclitaxel
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Sanofi
  • Most Recent Events

    • 01 Feb 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 02 Oct 2012 Planned end date changed from 1 Sep 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.
    • 02 Jul 2012 Planned end date changed from 1 Jun 2012 to 1 Sep 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top